title: Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients.
abstract: OBJECTIVE
  To review the current reproductive advances in insulin-sensitizing agents for treatment of polycystic ovary syndrome patients.
  
  
  RESULTS
  To date, among insulin-sensitizing drugs, only metformin should be used to improve reproductive function in well selected polycystic ovary syndrome patients. Preliminary data seem to show beneficial effects of thiazolidinediones in improving metabolic and hormonal patterns and in restoring regular menses.
  
  
  CONCLUSIONS
  The use of insulin-sensitizing drugs offers a new perspective for the treatment of polycystic ovary syndrome-related reproductive disorders. However, further data are needed before we can draw definitive conclusions regarding their clinical role.
authors.affiliation: Department of Obstetrics & Gynecology, University Magna Graecia of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Palomba
authors.forename: Angela
authors.initials: A
authors.lastname: Falbo
authors.forename: Francesco
authors.initials: F
authors.lastname: Orio
authors.forename: Fulvio
authors.initials: F
authors.lastname: Zullo
mesh_terms: D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced*; D011256:Pregnancy Outcome; D016032:Randomized Controlled Trials as Topic
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin